In data from the first stage of two NSCLC cohorts of ENCORE 601, including patients with PD-(L)1 refractory disease, as well as PD-(L)1 naïve patients, the observed overall response rate was 10% in patients who had progressed on prior anti-PD-1 or PD-(L)1 therapy and 24% in patients naïve to PD-1 or PD-(L)1 therapy.
Across both NSCLC cohorts, the responders with known PD-(L)1 expression levels were all observed to be low (1-49%) or negative expressors. Three patients from each cohort remain on therapy, and two of the six have been on the combination for over one year.
ENCORE 601 is an open-label, Phase 1b/2 clinical trial employing a Simon two-stage design to evaluate four patient populations: patients with non-small cell lung cancer (NSCLC) who have not previously received a PD-1 antagonist; patients with NSCLC who have progressed on a PD-1 antagonist; patients with advanced melanoma who have progressed on a PD-1 antagonist; and microsatellite stable colorectal cancer who have not previously been treated with a PD-1 antagonist.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company that focuses on the development and commercialization of therapies for various cancer indications.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review